Blutzuckersenkung durch den Phosphatbinder Sevelamer

Journal Club

Lowering of blood glucose by the phosphate binder sevelamer

Notes

Interessenkonflikt

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Ooi CP, Loke SC (2014) Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review. Diabet Med 31(1):2–14CrossRefPubMedGoogle Scholar
  2. 2.
    van Dijk TH, Grefhorst A, Oosterveer MH, Bloks VW, Staels B, Reijngoud DJ, Kuipers F (2009) An increased flux through the glucose 6‑phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice. J Biol Chem 284(16):10315–10323CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD (2013) Gonzalez FJ Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4:23844Google Scholar
  4. 4.
    Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S, Tanaka N, Desai D, Amin SG, Albert I, Patterson AD (2015) Gonzalez FJ Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125(1):386–402CrossRefPubMedGoogle Scholar
  5. 5.
    Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH, Liu Y, Gavrilova O, Patterson AD, Gonzalez FJ (2015) Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 6:10166CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Institut für klinische Diabetologie, Deutsches Diabetes-Zentrum an der Heinrich-Heine-UniversitätLeibniz-Zentrum für DiabetesforschungDüsseldorfDeutschland

Personalised recommendations